禁煙が血漿α－クロトに及ぼす影響 by 神薗 洋子
1 
 
 
Impact of cigarette smoking cessation on plasma α-klotho levels 
- VN-SEESAW-Klotho Study - 
 
Yoko Kamizono1,2, Yuhei Shiga2, Yasunori Suematsu2, Satoshi Imaizumi2,3, Hitomi 
Tsukahara4, Keita Noda5, Takashi Kuwano2, Kanta Fujimi2,6,  
Keijiro Saku2,7, Shin-ichiro Miura2,7. 
 
1International University of Health and Welfare, 2Department of Cardiology and 
3Clinical Research and Ethics Center, Fukuoka University School of Medicine, 
4Fukuoka University School of Nursing, 5Clinical Research Assist Center and 6Division 
of Rehabilitation, Fukuoka University Hospital, and 7Department of Molecular 
Cardiovascular Therapeutics, Fukuoka University School of Medicine, Fukuoka, Japan. 
 
Short title: Cigarette smoking cessation and α-klotho 
 
Correspondence: Shin-ichiro Miura, Department of Cardiology, Fukuoka University 
School of Medicine, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.  
Telephone +81-92-801-1011, Fax +81-92-865-2692 
e-mail miuras@cis.fukuoka-u.ac.jp 
 
  
2 
 
Abstract 
Smoking cessation reduces the risk of cardiovascular disease and improves clinical 
outcomes. We studied the effect of smoking cessation on plasma levels of α-klotho, 
which is an anti-aging protein. We treated 28 smokers (male:female=23:5, 46±12y) with 
varenicline (n=14) or a transdermal nicotine patch (n=14) as part of a 12-week smoking 
cessation program (the VN-SEESAW Study). Pulse rate, blood pressure, plasma levels 
of α-klotho, fibroblast growth factor (FGF)-19 and FGF-21, hemoglobin (Hb) and 
expiratory carbon monoxide (CO) concentration were measured before and after the 
anti-smoking intervention. Smoking cessation significantly decreased pulse rate, α-
klotho, Hb and CO concentration, but not FGF-19 or FGF-21 in all subjects. On the 
other hand, body mass index significantly increased after the intervention. Changes in 
α-klotho levels (values at week 12 minus the values at week 0) were negatively 
associated with α-klotho levels at week 0 and positively associated with changes in Hb 
levels. In addition, the successful smoking cessation group (n=21) showed significant 
reductions in pulse rate, systolic blood pressure, α-klotho, Hb and CO concentration. In 
conclusions, smoking cessation significantly decreased serum levels of the anti-aging 
molecule α-klotho. Our results are consistent with a previous report that an increase in 
α-klotho might be a compensatory response to smoking stress. 
Abbreviations: AMI = acute myocardial infarction, VN-SEESAW study = a trial of 
varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal 
symptoms, CO = end-expiratory carbon monoxide, BW = body weight, BMI = body 
mass index, SBP = systolic blood pressure, DBP = diastolic BP, PR = pulse rate, IRB = 
Independent Review Board, FGF = fibroblast growth factor, Hb = hemoglobin  
Key words: smoking cessation; α-klotho; hemoglobin; expiratory CO. 
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1. Introduction 
Cigarette smoking is a risk factor for various diseases and is one of the most critical 
coronary risk factors [1-3]. Smoking cessation reduces the risk of cardiovascular disease 
and improves clinical outcomes [4, 5]. The risk of acute myocardial infarction (AMI) 
has been reported to be substantially reduced one year after smoking cessation [6]. We 
previously reported that the spread of a non-smoking policy significantly decreased the 
in-hospital onset of AMI in our hospital [7]. Thus, smoking cessation is being actively 
promoted worldwide. 
Klotho is a well-known anti-aging molecule [8-12]. Overexpression of klotho in 
transgenic mice significantly extended their life span compared to that of wild-type 
mice [9]. Higher klotho levels have been associated with a lower prevalence of 
cardiovascular disease [10]. Low serum klotho levels have been associated with 
increased carotid artery intima-media thickness and epicardial fat thickness and with 
decreased flow-mediated dilation of the brachial artery, indicating that a low serum 
klotho level is a predictor of atherosclerosis [11]. On the other hand, in another study, 
serum levels of α-klotho in never-smokers were low, and smokers showed highly 
increased serum levels of α-klotho [12]. 
The life expectancy of smokers is at least one decade less than that of subjects 
who have never smoked. Smoking cessation before the age of 40 years reduces the risk 
of death associated with continued smoking by about 90 % [13]. Smokers may exhibit 
low-grade inflammation and inflammation in blood vessels may be improved by 
smoking cessation [14, 15]. The serum levels of the inflammation-related cytokine 
interleukin-6 were significantly higher in smokers than in never-smokers [12]. In 
addition, serum levels of α-klotho were correlated with interleukin-6 in middle-aged 
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never-smokers, but not in smokers [12]. However, little is known about the association 
between smoking cessation and this anti-aging molecule. Thus, we believe that it is 
important to study this association in Japanese smokers. In this study, we hypothesized 
that smoking cessation could lead to a compensatory response in α-klotho as an anti-
aging molecule, and therefore we evaluated α-klotho in participants before and after 
smoking cessation. 
 
2. Methods 
2.1. Study design 
Tsukahara et al. previously reported a randomized controlled open comparative trial of 
varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal 
symptoms (the VN-SEESAW study) [16]. Briefly, 32 Japanese adult smokers were 
enrolled for treatment at Fukuoka University Hospital. Participants either received 
varenicline for 12 weeks or wore a transdermal nicotine patch on the chest for 8 weeks. 
Successful smoking cessation was identified by both a self-assessment and the end-
expiratory carbon monoxide (CO) concentration (<8 ppm).  Body weight (BW), body 
mass index (BMI), systolic blood pressure (SBP), diastolic BP (DBP), and pulse rate 
(PR) were measured. The study protocol was approved by the Independent Review 
Board (IRB) of Fukuoka University Hospital [#7-05(08-27)], and all participants gave 
their written informed consent. Takata et al. performed an additional examination [VN-
SEESAW-HDL Study; IRB (#14-5-13)] of plasma lipid profiles [low-density 
lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride levels], high-
density lipoprotein subfractions, and cholesterol efflux capacity [17]. In the current 
investigation (VN-SEESAW-Klotho Study), we measured -klotho, fibroblast growth 
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factor (FGF)-19, FGF-21 and hemoglobin (Hb) in blood samples obtained at baseline (0 
weeks) and at 12 weeks in both the varenicline and nicotine patch groups. The current 
study after modification was also approved by the IRB of Fukuoka University Hospital. 
 
2.2. Measurement of plasma levels of -klotho, FGF-19 and FGF-21 
Plasma levels of -klotho, FGF-19 and FGF-21 were measured using commercial 
sandwich enzyme immunoassay kits according to the respective manufacturer’s 
instructions (Quantikine®
 
ELISA Human FGF-19 and FGF-21 Immunoassay kits were 
purchased from R&D Systems, Minneapolis, MN, and a Human soluble α-Klotho 
Assay Kit was purchased from Immuno-Biological Laboratories Co, Ltd., 
Gumma, Japan)  
 
2.3. Statistical analysis 
Data are presented as the mean ± standard deviation. Changes were calculated as the 
values after 12 weeks minus the values at week 0. Differences between values at 
baseline and after 12 weeks were evaluated with the paired t-test. The associations 
between two parameters were assessed by Spearman’s rank correlation coefficient. 
Differences between the successful and unsuccessful smoking cessation groups or the 
varenicline and nicotine patch groups were evaluated with the unpaired t-test. A P value 
of less than 0.05 was considered statistically significant. Analyses were performed using 
the Stat View statistical software package (Stat View 5; SAS Institute Inc., Cary, NC, 
USA). 
 
3. Results 
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3.1.Patient characteristics and various parameters at weeks 0 and 12 in all 
participants 
Twenty-eight participants (14 for varenicline, 14 for a nicotine patch) were analyzed 
(Table 1, Figure 1). In all participants, PR, plasma levels of α-klotho (Figure 1A), Hb 
and CO concentration were significantly decreased after 12 weeks, whereas there were 
no changes in FGF-19 or FGF-21 (Figure 1BC). On the other hand, there were 
significant increases in BW and BMI after 12 weeks. 
 
3.2. Patient characteristics and various parameters at weeks 0 and 12 in the 
successful and unsuccessful smoking cessation groups 
Seven of the 28 participants did not stop smoking (Table 2). The proportions of 
participants in the unsuccessful smoking cessation group were not significantly different 
between those who received varenicline (4 participants) and a nicotine patch (3 
participants). There were no statistically significant differences in BW, BMI, α-klotho, 
FGF-19, FGF-21, CO concentration or Hb between the successful and unsuccessful 
groups at week 0. After 12 weeks, both groups showed significant reductions in α-
klotho (Figure 2A), Hb and CO concentration. PR and SBP in the successful group, but 
not the unsuccessful group, significantly decreased between baseline and 12 weeks, 
whereas there were significant increases in BW and BMI after 12 weeks in the 
successful group. 
 
3.3. Patient characteristics and various parameters at weeks 0 and 12 in the 
varenicline and nicotine patch groups 
We also analyzed the differences in characteristics of the participants and various 
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parameters between the varenicline and nicotine patch groups (Table 3). There were no 
statistically significant differences in BW, BMI, α-klotho, FGF-19, FGF-21, CO 
concentration or Hb between the at week 0. After 12 weeks, both groups showed 
significant reductions in α-klotho (Figure 2B), CO concentration and Hb. BW and BMI 
in both groups significantly increased after 12 weeks. 
 
3.4. Associations between α-klotho and Hb or CO concentration 
Figure 3 shows the associations between α-klotho and Hb or CO concentration. The 
change in the plasma level of α-klotho from week 0 to week 12 (Δ= the value at week 
12 minus the value at week 0) was negatively associated with α-klotho at week 0 and 
positively associated with ΔHb (Figure 3AB). On the other hand, there were no 
associations between Δα-klotho and ΔCO or ΔHb (Figure 3CD). 
 
4. Discussion 
In this study, smoking cessation significantly decreased serum levels of the anti-aging 
molecule α-klotho, which suggests that an increase in α-klotho may be a compensatory 
response to smoking stress. 
We hypothesized that smoking cessation could lead to a compensatory response 
in α-klotho as an anti-aging molecule. We found that smoking cessation significantly 
decreased plasma levels of α-klotho. Higher klotho levels have been associated with a 
reduced risk of cardiovascular disease, and lower levels were associated with the 
progression of atherosclerosis [10, 11]. Since all of the participants in this study were 
smokers, we did not analyze α-klotho levels before they began smoking. Nakanishi et 
al. reported that α-klotho levels in never-smokers were low, while those in smokers 
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were very high [12]. In addition, serum α-klotho was positively correlated with the pro-
inflammatory molecule interleukin-6 [12], and has been reported to act as an anti-
inflammatory molecule [18]. The positive correlation suggested that the increase in 
serum levels of α-klotho might be a compensatory response to smoking stress. In this 
study, Δα-klotho was negatively associated with α-klotho at week 0. Thus, the α-klotho 
levels in our participants were upregulated by smoking, and smoking cessation may 
produce a compensatory decrease in these levels. Our results were in agreement with 
those in a previous report [12]. 
The levels of FGF-19 and FGF-21 were not significantly decreased after 12 
weeks in this study. β-klotho, which is a homolog of α-klotho, interacts with FGF-19, 
which is a known regulator of bile acid homeostasis [19], and with FGF-21, which 
regulates the metabolism [20]. Although smoking cessation should reduce FGF-21 
levels, since smoking increased serum levels of FGF-21 [12], these levels did not 
change and BMI significantly increased after smoking cessation in this study. Serum 
levels of FGF-21 have been shown to increase in subjects with metabolic syndrome and 
atherosclerosis [21], and this could explain why FGF-21 levels did not change after 
smoking cessation. Since no prior studies have examined the influence of smoking 
cessation on changes in FGF-19 and FGF-21, further studies are needed to clarify these 
changes.   
Another important result in this study was that PR, Hb and CO concentration 
significantly decreased after 12 weeks in all patients. The successful smoking cessation 
group showed significant reductions in PR, SBP, Hb and CO concentration, and all of 
these reductions in this group were reasonable. A meta-analysis supported an 
association between heavy smoking and a high resting heart rate [22]. Moreover, heavy 
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smoking is associated with a persistent rise in BP and with an increase in BP variability 
[23]. Since smokers had significantly higher levels of Hb [24], the level of Hb may 
significantly decrease after smoking cessation, with a reduction of the CO 
concentration. Δα-klotho was positively associated with ΔHb. Decreased α-klotho levels 
are associated with decreased Hb in patients with chronic kidney disease [25]. Under 
hypoxic conditions, erythropoietin stimulates the differentiation of erythroid progenitor 
cells and normoblasts to increase the amount of red blood cells [26]. Erythropoietin 
promotes the expression of α-klotho and an increase in α-klotho suppresses the 
production of erythropoietin [26, 27]. After smoking cessation, hypoxic conditions 
improve and erythropoietin may not be needed to stimulate differentiation to increase 
red blood cells, and consequently erythropoietin may not promote the expression of α-
klotho. 
This study has several limitations. For example, the sample size was small, which 
limits our ability to generalize the results. Furthermore, this study assessed α-klotho 
levels only over the short term. The long-term effect of smoking cessation on α-klotho 
will need to be elucidated in the future. 
In conclusion, our results agree with those of a previous report that an increase in 
α-klotho might be a compensatory response to smoking stress. 
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Figure legends 
Figure 1. 
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Plasma levels of α-klotho (A), fibroblast growth factor (FGF)-19 (B) and FGF-21 (C) at 
weeks 0 and 12 in all patients.  
 
Figure 2.  
Plasma levels of α-klotho in the successful and unsuccessful smoking cessation groups 
(A) and in the varenicline and nicotine patch groups (B). 
 
Figure 3.  
Associations between Δα-klotho and the α-klotho level at week 0 (A), Δα-klotho and 
ΔHb (B), Δα-klotho and ΔCO concentration (C), and ΔHb and ΔCO concentration (D).  
Δ indicates the value at week 12 minus the value at week 0. 
Table 1. Patient characteristics and various parameters at weeks 0 and 12 in all participants. 
 Week 0 Week 12 p value  
BW, kg 
BMI, kg/m2 
PR, bpm 
SBP, mmHg 
DBP, mmHg 
-klotho, pg/ml 
FGF-19, pg/ml 
FGF-21, pg/ml 
CO, ppm 
Cr, mg/dl 
Hb, g/dl 
66.7±11.2 
23.7±3.4 
78±9 
129±18 
78±10 
520±92 
248±134 
240±260 
26.6±11.2 
0.8±0.1 
15.0±1.2 
68.7±11.5 
24.4±3.5 
72±10 
125±15 
77±11 
465±85 
266±260 
198±150 
7.2±8.2 
0.8±0.2 
14.5±1.1 
<0.001 
<0.001 
0.007 
0.164 
0.625 
<0.001 
0.735 
0.245 
<0.001 
0.259 
<0.001 
 
Data are presented as the mean ± standard deviation. BW, body weight; BMI, body mass index; PR, pulse rate; SBP, 
systolic blood pressure; DBP, diastolic BP; FGF, fibroblast growth factors; CO, carbon monoxide; Cr, creatinine; Hb, 
hemoglobin. 
  
Table 2. Patient characteristics and various parameters at weeks 0 and 12 in the successful and 
unsuccessful smoking cessation groups. 
 Successful group (n=21)  Unsuccessful group  (n=7) 
 Week 0 Week 12 p value  Week 0 Week 12 p value 
BW, kg 
BMI, kg/m2 
PR, bpm 
SBP, mmHg 
DBP, mmHg 
-klotho, pg/ml 
FGF-19, pg/ml 
FGF-21, pg/ml 
CO, ppm 
Cr, mg/dl 
Hb, g/dl 
67.1±12.7 
23.7±3.8 
77±9 
130±19 
78±11 
538±97 
237±128 
230±277 
22.3±9.6 
0.8±0.1 
15.0±1.2 
69.1±12.9 
24.5±3.8 
70±11 
124±15 
70±11 
487±84 
254±280 
181±131 
4.1±1.8 
0.8±0.2 
14.5±1.1 
<0.0001 
<0.0001 
0.016 
0.039 
0.473 
<0.0001 
0.807 
0.359 
<0.0001 
0.452 
0.001 
 65.8±4.9 
23.4±2.0 
79±10 
125±14 
79±5 
467±43 
277±155 
260±232 
37.9±7.9 
0.8±0.2 
15.3±1.0 
67.5±5.9 
24.1±2.7 
76±7 
130±16 
80±11 
399±50 
297±225 
232±195 
16.6±12.4 
0.9±0.2 
14.6±1.4 
0.087 
0.079 
0.230 
0.327 
0.782 
0.010 
0.791 
0.398 
0.002 
0.356 
0.018 
Data are presented as the mean ± standard deviation. BW, body weight; BMI, body mass index; PR, pulse rate; SBP, 
systolic blood pressure; DBP, diastolic BP; FGF, fibroblast growth factors; CO, carbon monoxide; Cr, creatinine; Hb, 
hemoglobin. 
  
Table 3. Patient characteristics and various parameters at weeks 0 and 12 in the varenicline and 
nicotine patch groups.  
 Varenicline group (n=14)  Nicotine patch group (n=14) 
 Week 0 Week 12 p value  Week 0 Week 12 p value 
BW, kg 
BMI, kg/m2 
PR, bpm 
SBP, mmHg 
DBP, mmHg 
-klotho, pg/ml 
FGF-19, pg/ml 
FGF-21, pg/ml 
CO, ppm 
Cr, mg/dl 
Hb, g/dl 
67.3±9.0 
23.7±3.3 
79±11 
127±16 
77±11 
488±87 
285±145 
131±73 
27.9±9.8 
0.8±0.1 
14.9±1.1 
69.2±9.6 
24.4±3.4 
73±9 
126±16 
76±11 
440±83 
239±155 
172±110 
5.4±4.1 
0.8±0.2 
14.3±1.1 
0.005 
0.004 
0.610 
0.863 
0.440 
0.004 
0.419 
0.044 
<0.0001 
0.583 
0.001 
 66.2±13.3 
23.6±3.6 
77±8 
131±20 
78±10 
553±87 
215±120 
349±328 
25.3±12.7 
0.8±0.1 
15.2±1.2 
68.3±13.4 
24.4±3.7 
71±12 
124±16 
78±11 
489±84 
291±335 
224±185 
9.1±10.7 
0.8±0.1 
14.7±1.2 
0.002 
0.002 
0.070 
0.105 
0.966 
<0.0001 
0.403 
0.057 
<0.0001 
0.272 
0.018 
Data are presented as the mean ± standard deviation. BW, body weight; BMI, body mass index; PR, pulse rate; SBP, 
systolic blood pressure; DBP, diastolic BP; FGF, fibroblast growth factors; CO, carbon monoxide; Cr, creatinine; Hb, 
hemoglobin. 
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